Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Cholangiocarcinoma | Research

Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma

Authors: Khaa Hoo Ong, Hong-Yue Lai, Ding-Ping Sun, Tzu-Ju Chen, Steven Kuan-Hua Huang, Yu-Feng Tian, Chia-Lin Chou, Yow-Ling Shiue, Ti-Chun Chan, Chien-Feng Li, Yu-Hsuan Kuo

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Cholangiocarcinoma is the most common malignant bile duct tumor in Southeast Asia. The special location of cholangiocarcinoma leads to it being difficult to diagnose. Currently, the progress in clinical prognosis outcomes remains abysmal owing to the lack of definitive diagnostic criteria. Therefore, uncovering the potential markers for cholangiocarcinoma is a pressing issue. Ubiquitin-conjugating enzyme E2 C (UBE2C) is a critical ubiquitination enzyme; it is involved in the tumorigenesis of various malignancies and affects the patient’s prognosis. However, there is currently no relevant literature to indicate whether UBE2C is related to the clinical survival outcome of cholangiocarcinoma patients. In this report, we mined the published cholangiocarcinoma transcriptome data set (GSE26566), compared it with the ubiquitination-associated gene (GO:0016567), and identified that UBE2C was highly expressed in cholangiocarcinoma tumor tissue. Moreover, high expression of UBE2C was markedly correlated with surgical margin, primary tumor, histological variants, and histological grade. More specifically, high expression of UBE2C was negatively associated with overall survival, disease-specific survival, local recurrence-free survival, and metastasis-free survival in patients with cholangiocarcinoma. Our findings demonstrate that UBE2C may provide a potential therapeutic marker and prognostic factor for cholangiocarcinoma patients.
Appendix
Available only for authorised users
Literature
1.
2.
Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Emergence of intrahepatic cholangiocarcinoma: how high-throughput technologies expedite the solutions for a rare cancer type. Front Genet. 2018;9:309.PubMedPubMedCentralCrossRef
3.
Terai K, Ishigaki K, Kagawa Y, Okada K, Yoshida O, Sakurai N, et al. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009–2021). J Am Vet Med Assoc. 2022;260:1–7.CrossRef
4.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.PubMedPubMedCentralCrossRef
5.
Alsaleh M, Leftley Z, Barbera TA, Sithithaworn P, Khuntikeo N, Loilome W, et al. Cholangiocarcinoma: a guide for the nonspecialist. Int J Gen Med. 2019;12:13–23.PubMedCrossRef
6.
Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic sequential therapy of CisGem, tislelizumab, and lenvatinib for advanced intrahepatic cholangiocarcinoma conversion therapy. Front Oncol. 2021;11:691380.PubMedPubMedCentralCrossRef
7.
Chan KM, Tsai CY, Yeh CN, Yeh TS, Lee WC, Jan YY, et al. Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol. 2018;18(1):180.PubMedPubMedCentralCrossRef
8.
Gkika E, Hawkins MA, Grosu AL, Brunner TB. The evolving role of radiation therapy in the treatment of biliary tract cancer. Front Oncol. 2020;10:604387.PubMedPubMedCentralCrossRef
9.
Du X, Song H, Shen N, Hua R, Yang G. The molecular basis of ubiquitin-conjugating enzymes (E2s) as a potential target for cancer therapy. Int J Mol Sci. 2021;22(7):3440.PubMedPubMedCentralCrossRef
10.
11.
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003;63(14):4167–73.PubMed
12.
Liu Y, Huang F, Chen H, Peng Q, Zhao C, Miao L. Expression of UBE2C in lung adenocarcinoma based on database analysis and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020;45(9):1044–52.PubMed
13.
Li R, Pang XF, Huang ZG, Yang LH, Peng ZG, Ma J, et al. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC Cancer. 2021;21(1):996.PubMedPubMedCentralCrossRef
14.
Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121(1):33–8.PubMedCrossRef
15.
Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, et al. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 2013;13:192.PubMedPubMedCentralCrossRef
16.
Qin T, Huang G, Chi L, Sui S, Song C, Li N, et al. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomed Pharmacother. 2017;95:649–55.PubMedCrossRef
17.
Gong Y, Wang D, Lin L, Dai J, Yu L. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance. Medicine. 2019;98(46):e17896.PubMedPubMedCentralCrossRef
18.
Liu Y, Zhao R, Chi S, Zhang W, Xiao C, Zhou X, et al. UBE2C is upregulated by estrogen and promotes epithelial-mesenchymal transition via p53 in endometrial cancer. Mol Cancer Res. 2020;18(2):204–15.PubMedCrossRef
19.
Kim YJ, Lee G, Han J, Song K, Choi JS, Choi YL, et al. UBE2C overexpression aggravates patient outcome by promoting estrogen-dependent/independent cell proliferation in early hormone receptor-positive and HER2-negative breast cancer. Front Oncol. 2019;9:1574.PubMedCrossRef
20.
Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell Death Discov. 2022;8(1):130.PubMedPubMedCentralCrossRef
21.
Chiang AJ, Li CJ, Tsui KH, Chang C, Chang YI, Chen LW, et al. UBE2C drives human cervical cancer progression and is positively modulated by mTOR. Biomolecules. 2020;11(1):37.PubMedPubMedCentralCrossRef
22.
Zhang HQ, Zhao G, Ke B, Ma G, Liu GL, Liang H, et al. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2018;22(6):1665–71.PubMed
23.
Chan TC, Wu WJ, Li WM, Shiao MS, Shiue YL, Li CF. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020;10(25):11775–93.PubMedPubMedCentralCrossRef
24.
Liu J, Ren WX, Shu J. Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma. Insights Imaging. 2022;13(1):10.PubMedPubMedCentralCrossRef
25.
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783–91.PubMedCrossRef
26.
27.
Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 2021;149:321–87.PubMedCrossRef
28.
Tischoff I, Wittekind C, Tannapfel A. Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2006;13(4):274–9.PubMedCrossRef
29.
30.
Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31.PubMedCrossRef
31.
Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, et al. Molecular mechanisms linking risk factors to cholangiocarcinoma development. Cancers. 2022;14(6):1442.PubMedPubMedCentralCrossRef
32.
Cholangiocarcinoma WG. Italian clinical practice guidelines on cholangiocarcinoma—part I: classification, diagnosis and staging. Dig Liver Dis. 2020;52(11):1282–93.CrossRef
33.
Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvise M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107.PubMedCrossRef
34.
Nicolau-Neto P, Palumbo A, De Martino M, Esposito F, de Almeida ST, Fusco A, et al. UBE2C is a transcriptional target of the cell cycle regulator FOXM1. Genes. 2018;9(4):188.PubMedPubMedCentralCrossRef
35.
Wang R, Song Y, Liu X, Wang Q, Wang Y, Li L, et al. UBE2C induces EMT through Wnt/betacatenin and PI3K/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int J Oncol. 2017;50(4):1116–26.PubMedPubMedCentralCrossRef
36.
Jin Z, Zhao X, Cui L, Xu X, Zhao Y, Younai F, et al. UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020;523(2):389–97.PubMedCrossRef
37.
Zhang CY, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. World J Hepatol. 2022;14(5):956–71.PubMedPubMedCentralCrossRef
38.
Kariri Y, Toss MS, Alsaleem M, Elsharawy KA, Joseph C, Mongan NP, et al. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Res Treat. 2022;192(3):529–39.PubMedPubMedCentralCrossRef
39.
Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630–41.PubMedCrossRef
40.
Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y, et al. CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Med Sci Monit. 2020;26:e925289.PubMedPubMedCentralCrossRef
41.
Suzuki A, Badger BL, Haase J, Ohashi T, Erickson HP, Salmon ED, et al. How the kinetochore couples microtubule force and centromere stretch to move chromosomes. Nat Cell Biol. 2016;18(4):382–92.PubMedPubMedCentralCrossRef
42.
Chen X, Li W, Xiao L, Liu L. Nuclear division cycle 80 complex is associated with malignancy and predicts poor survival of hepatocellular carcinoma. Int J Clin Exp Pathol. 2019;12(4):1233–47.PubMedPubMedCentral
43.
44.
Zhang D, Liu E, Kang J, Yang X, Liu H. MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma. Oncotarget. 2017;8(54):93014–28.PubMedPubMedCentralCrossRef
45.
Yang J, Huang Y, Song M, Pan Q, Zhao J, He J, et al. SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK/AKT/Notch1 signaling pathway. Int J Biol Sci. 2022;18(14):5241–59.PubMedPubMedCentralCrossRef
Metadata
Title
Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma
Authors
Khaa Hoo Ong
Hong-Yue Lai
Ding-Ping Sun
Tzu-Ju Chen
Steven Kuan-Hua Huang
Yu-Feng Tian
Chia-Lin Chou
Yow-Ling Shiue
Ti-Chun Chan
Chien-Feng Li
Yu-Hsuan Kuo
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01575-9

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Review

Intention to use maternal waiting home and its predictors among pregnant women in Ethiopia: systematic review and meta-analysis

Review

From nitrate to NO: potential effects of nitrate-reducing bacteria on systemic health and disease

Research

Activation of the p53 signaling pathway by piRNA-MW557525 overexpression induces a G0/G1 phase arrest thus inhibiting neuroblastoma growth

Research

Validity of distal radius fracture diagnoses in the Swedish National Patient Register

Research

Association between spinal muscular atrophy type and delayed diagnosis and the risk of spinal deformity in Indonesian patients

Research

Association of blood pressure trajectories with coronary heart disease among the disabled population in Shanghai, China: a cohort study of 7 years following up